Leo Cancer Care has raised $65 million in an oversubscribed Series D financing to accelerate the commercialization of its integrated upright cancer care platform across proton therapy, photon therapy, and imaging.
The round was led by Yu Galaxy, with participation from new investor Eventide Asset Management and existing backers. The funding will support manufacturing scale-up, commercial deployment, and continued clinical and product development.
Related: NeuroBell secures €5m in new funding for US launch
The financing follows a key clinical milestone in June 2026, when Stanford Medicine delivered the world’s first compact upright proton therapy treatment using Leo’s Marie® platform. The company’s FDA-cleared upright imaging system is also designed to support future applications across radiology.
Leo says its upright approach is designed to improve patient positioning, reduce treatment room size by eliminating the need for large rotating gantries, and enhance the treatment experience by allowing patients to remain upright and in communication with clinicians.
CEO and co-founder Stephen Towe said:
“This financing lets us accelerate that platform strategy across proton, photon and imaging.”
The company also announced a strategic partnership with an international healthcare company, with further details expected in the coming weeks.
